CDKN2A and ameloblastoma: Not least, molecular analysis as used in a study has also highlighted a statistically significant presence of p16 mutation (cyclin dependent kinase inhibitor 2A) in all cases of AC samples as compared to observation in only one sample of ameloblastoma [40].